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Sexually transmitted infectionsRenewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked by the increasing
threat of gonococcal antimicrobial resistance (AMR) and growing optimism that gonococcal vaccines are
biologically feasible. Evidence suggests serogroup B Neisseria meningitidis vaccines might provide some
cross-protection against N. gonorrhoeae, and new gonococcal vaccine candidates based on several
approaches are currently in preclinical development. To further stimulate investment and accelerate devel-
opment of gonococcal vaccines, greater understanding is needed regarding the overall value that gonococcal
vaccines might have in addressing public health and societal goals in low-, middle-, and high-income coun-
try contexts and how future gonococcal vaccines might be accepted and used, if available. In January 2019,
the World Health Organization (WHO) convened a multidisciplinary international group of experts to lay
the groundwork for understanding the potential health, economic, and societal value of gonococcal vaccines
and their likely acceptance and use, and for developing gonococcal vaccine preferred product characteristics
(PPCs). WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and
use in meeting the global public health need. This paper describes the main discussion points and conclu-
sions from the January 2019 meeting of experts. Participants emphasized the need for vaccines to control N.
gonorrhoeae infections with the ultimate goals of preventing adverse sexual and reproductive health out-
comes (e.g., infertility) and reducing the impact of gonococcal AMR. Meeting participants also discussed
important PPC considerations (e.g., vaccine indications, target populations, and potential immunization
strategies) and highlighted crucial research and data needs for guiding the value assessment and PPCs for
gonococcal vaccines and advancing gonococcal vaccine development.





Box 1 Global public health strategies and initiatives relevant
to gonococcal vaccines.
Decade of Vaccines and Global Vaccine Action Plan 2011–
2020 [78,79]
Global, collaborative initiative that includes a call for new
research to expand the benefits of vaccines. A post-2020 plan
‘‘Immunization Agenda 2030” will be presented for endorse-
ment by the World Health Assembly during 2020.
Global Strategy for Women’s, Children’s and Adolescents’
Health (Every Woman, Every Child, 2015) [80]
Prevention of sexually transmitted infections (STIs) (e.g.,
gonorrhoea) is part of global efforts for improving pregnancy
outcomes, maternal and child health, adolescent health, and
sexual and reproductive health.
World Health Organization (WHO) Global Health Sector
Strategy on STIs, 2016–2021 [3]
Gonorrhoea is 1 of 3 STIs prioritized for strategic global
focus; 1 of 4 targets for 2030 is a 90% reduction in gonorrhoea
incidence globally against a 2018 global baseline. In addition,
STI vaccines are noted as key innovations needed for sustain-
able STI control.
Global Roadmap for Advancing Development of Vaccines
Against STIs [6,7,77]
Collaborative global effort initiated by WHO and the National
Institute of Allergy and Infectious Diseases (NIAID) that outlines
crucial action steps for advancing vaccine development for STI
vaccines, including gonococcal vaccines.
WHO Global Action Plan on Antimicrobial Resistance (2015)
[81]
Development and use of new or improved vaccines that can
prevent diseases that are becoming difficult to treat or are
untreatable because of antimicrobial resistance (AMR) is a
key area of focus.
WHO Global Priority List of Antibiotic-Resistant Bacteria to
Guide Research, Discovery, and Development of New Anti-
biotics (2017) [37]
Neisseria gonorrhoeae is categorized as a high-priority patho-
gen for research and development efforts.
WHO Global Action Plan to Control the Spread and Impact
of Antimicrobial Resistance in Neisseria gonorrhoeae
(2012) [82]
Provides guidance regarding strategies for containing the
spread of AMR in N. gonorrhoeae as part of broader national
and international strategies for STI prevention and control.
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Gonorrhoea, a sexually transmitted infection (STI) caused by the
bacterium Neisseria gonorrhoeae (the gonococcus), has been a per-
sistent public health problem for centuries. An estimated 87 mil-
lion new cases occurred worldwide in 2016 [1]. Increased
emergence of N. gonorrhoeae antimicrobial resistance (AMR) has
heightened the possibility of future untreatable infections, and this
threat to sexual and reproductive health (SRH) has increased global
concern [2]. Untreated, or inadequately treated, gonorrhoea can
lead to pelvic inflammatory disease (PID), infertility, adverse preg-
nancy outcomes, elevated risk for HIV acquisition and transmis-
sion, and ongoing transmission of N. gonorrhoeae to sexual
partners and neonates. TheWorld Health Organization (WHO) Glo-
bal Health Sector Strategy on STIs has set targets for reducing gon-
orrhoea incidence by 90% by 2030 [3]. Recognizing that sustainable
control of N. gonorrhoeae infections might not be achievable with
current interventions, WHO’s strategy also highlights the crucial
need for such new innovations for fighting this STI as effective vac-
cines. Interest in gonococcal vaccine development has been rein-
vigorated not only by an increasing global emphasis on vaccines
in fighting AMR (see Box 1) [4], but also by observational studies
indicating that vaccines developed for serogroup B Neisseria menin-
gitidis might offer some protection against gonorrhoea, providing
promise that gonococcal vaccines are biologically feasible [5].
The Global STI Vaccine Roadmap outlines important action
steps for advancing vaccine development for STIs, including gonor-
rhoea [6,7]. WHO is coordinating key workstreams of the roadmap
to evaluate the predicted global health, economic, and societal
value of new STI vaccines and to identify vaccine attributes that
can help optimize the value while vaccine candidates are still in
early stages of development. To lay the groundwork for under-
standing the potential value of gonococcal vaccines and for devel-
oping gonococcal vaccine preferred product characteristics (PPCs),
[8] WHO convened a global, multidisciplinary consultation in Gen-
eva, Switzerland, in January 2019. The consultation included
experts in gonorrhoea basic science, microbiology, epidemiology,
clinical care, and public health control programmes, from low-
and middle-income countries (LMICs) and high-income countries
(HICs), along with experts in vaccine development and industry
observers. The meeting was convened to discuss (1) the global
public health need and goals for gonococcal vaccines and the value
such vaccines might offer; (2) key considerations for gonococcal
vaccine PPCs, in particular vaccine indications, target populations,
and programmatic delivery approaches; and (3) vital research and
data needs for building the value assessment and PPCs and advanc-
ing gonococcal vaccine development. This paper describes the
main discussion points and conclusions from the meeting.Vaccines to tackle drug resistant infections: An evaluation
of R&D opportunities (Wellcome Trust and Boston Consult-
ing Group, 2017) [4]
Assesses the potential of vaccines to combat AMR for multi-
ple pathogens; highlighted the strong case for advancing
early research and development for N. gonorrhoeae vaccines.
NIAID Workshop: Gonorrhoea Vaccines: the Way Forward
(2015) [83]
Workshop report outlines key preclinical and clinical develop-
ment pathway considerations for gonococcal vaccines.2. The need for gonococcal vaccines
2.1. N. gonorrhoeae infection and disease
N. gonorrhoeae typically infects urogenital, rectal, or oropharyn-
geal mucosae but can also cause conjunctival infection. Transmis-
sion of N. gonorrhoeae through penile–vaginal sex is efficient, with
a substantial proportion of people becoming infected after a single
exposure [9]. Among men, lower-genital tract infection typically
manifests as urethritis, with purulent discharge or dysuria in the
majority of cases. Among women, gonorrhoea primarily presents
as asymptomatic or minimally symptomatic cervical infection that
is often unrecognized or mistaken for other reproductive tract
infections [10]. Coinfections, particularly with Chlamydia tra-
chomatis, the causative agent of chlamydia, occur frequently [11].
N. gonorrhoeae can also be transmitted through oral–genital, geni-tal–anal, and oral–anal contact [12]. Among both sexes, oropharyn-
geal and rectal infections are usually asymptomatic but can result
in clinically apparent pharyngitis and proctitis, respectively.
The most common severe complication of gonorrhoea is upper-
genital tract infection among women. Although data are limited
regarding the proportion of N. gonorrhoeae cervical infections that
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PID, a common lower abdominal pain syndrome among young
women [13]. Damage to the fallopian tubes from PID can lead to
infertility, ectopic pregnancy, and chronic pelvic pain. Studies of
women with documented PID suggest 15%–20% will have infertil-
ity later [14–16]. Gonorrhoea can also lead to infertility through
subclinical or unrecognized PID [17]. Data regarding the conse-
quences of PID have been collected primarily in HICs and have
demonstrated that risk for sequelae is proportional to the delay
in initiating treatment [18]. In areas with limited access to ade-
quate health care for PID, a greater proportion of gonococcal infec-
tions might result in adverse outcomes. Ascending infection is now
uncommon among men, primarily because infections are more
likely to be symptomatic and promptly treated, but possible com-
plications include epididymoorchitis and urethral stricture [10].
Gonorrhoea among pregnant women has been associated with
risk for spontaneous abortion, intrauterine growth restriction, pre-
mature rupture of membranes, preterm birth, low infant birth-
weight, chorioamnionitis, and postpartum endometrial infection
[19]. However, precise risks for each outcome have not been
well-defined. Perinatal transmission of N. gonorrhoeae can result
in neonatal conjunctivitis, a frequent cause of blindness before
institution of topical ocular antibiotic prophylaxis for neonates
globally [20,21]. Additionally, epidemiologic and biologic data
indicate a link between such inflammatory STIs as gonorrhoea with
a 2- to 3-fold increased risk for HIV infection [22–24]. In the pres-
ence of N. gonorrhoeae infection, genital HIV RNA load increases,
thus also increasing HIV transmissibility [25]. Rare complications
of gonorrhoea include disseminated gonococcal infection, with
bacteraemia and systemic involvement.
2.2. Epidemiology of N. gonorrhoeae infection and disease
WHO estimated the global prevalence of urogenital gonococcal
infection to be 0.9% among women and 0.7% among men during
2016, with regional differences reflecting greater overall preva-
lence within LMICs [1]. Gonorrhoea prevalence ranged from 0.3%
among both sexes in the WHO European Region to 1.9% among
women and 1.6% among men in the African Region. However,
regional estimates can mask wide variations by country. For exam-
ple, general-population estimates of gonorrhoea prevalence have
ranged from <0.1% during 2010–2012 in England [26], to 6.6%
among women in South Africa [27], to >14% in antenatal clinics
in Papua New Guinea [28]. The estimated global incidence rate,
or new gonococcal infections, during 2016 was 20/1000 women
and 26/1000 men, translating to 87 million (95% uncertainty inter-
val: 59–123 million) new cases worldwide [1].
Prevalence and incidence of gonococcal infections vary both
between and within countries and, in all settings, are likely to be
higher among key populations, including men who have sex with
men (MSM) and sex workers [9]. In a meta-analysis among studies
of HIV preexposure prophylaxis (PrEP), gonorrhoea incidence
among MSM was approximately 40/100 person-years [29]. Within
HICs with low overall incidence, rates can be several-fold higher
for racial, ethnic, or other marginalized minority populations with
historical barriers to health care access [9,30].
Additionally, recent surveillance data from several HICs reveal
substantial and steady increases in gonorrhoea case reports where
gonorrhoea prevalence and incidence had previously been low. For
example, gonorrhoea case reports increased 83% in the United
States during 2009–2018 [31] and 80% in Australia during 2013–
2017 [30], and diagnoses increased 26% in just 1 year during
2017–2018 in England [32]. These increases have been greatest
among adolescents and young adults and among MSM. Several
health jurisdictions have observed an association between PrEP
scale-up for HIV prevention and increases in gonorrhoea incidence[33]. Surveillance assessments within LMICs have been limited by
less-developed infrastructure for testing and case reporting.
The global burden of gonococcal PID, infertility, ectopic preg-
nancy, and other adverse outcomes has not been quantified with
precision but might be substantial. During the 1980s, a large study
reported that approximately 85% of female infertility in sub-
Saharan Africa was caused by tubal scarring from genital infection
[34]. However, few studies have been conducted since then to
quantify the burden of tubal factor infertility in different settings
and the likelihood that gonorrhoea was a contributing factor. Many
of the adverse outcomes of gonorrhoea can have multiple infec-
tious causes, and lack of affordable diagnostic tests in LMICs limits
routine etiologic assessment. Outcomes such as infertility and
ectopic pregnancy might only be recognized years after infection.
2.3. AMR
Eversinceantibioticshavebeenavailable for treatinggonorrhoea,
N. gonorrhoeae has demonstrated its ability to develop or acquire
resistance rapidly to multiple antibiotics through different mecha-
nisms [35]. N. gonorrhoeae is a WHO high-priority pathogen for
research and development, because of increasing AMR to extended
spectrum cephalosporins, the only remaining first-line monother-
apy for gonorrhoea [2,36,37].Monitoring for gonococcal AMR is per-
formed at the global level throughWHO’s Gonococcal Antimicrobial
SurveillanceProgramme(GASP) laboratorynetwork,which includes
67 participating countries [2]. During 2009–2014, 66% of participat-
ing countries reported isolates with decreased susceptibility to
extended spectrum cephalosporins [36]. During 2015–2016, a total
of7countries,primarily inWHOWesternPacificandSoutheastAsian
Regions, reported >5% of isolates with decreased susceptibility, or
resistance, to ceftriaxone [2]. The majority of countries reporting to
GASP are HICs, and data are lacking in many settings [2].
Verified clinical treatment failures with extended spectrum
cephalosporins have occurred in several countries since the early
2000s [2,38]. Additionally, one treatment failure with recom-
mended ceftriaxone plus azithromycin dual therapy has now been
confirmed [39]. Treating pharyngeal infections successfully with
antibiotics is difficult, potentially because of reduced bioavailabil-
ity in the oropharynx, resulting in more treatment failures relative
to anogenital infections [2,40].
2.4. Existing interventions for gonorrhoea management and control
Primary prevention for gonorrhoea consists of comprehensive
sex education and condom promotion, which is essential but has
had limited and unsustained success, particularly as condom use
among MSM and other populations has decreased during the era of
PrEP and other biomedical HIV prevention strategies [33]. WHO
guidelines for gonorrhoea treatment recommend dual therapywith
an extended spectrum cephalosporin plus azithromycin as a single
dose [21]. Azithromycin also provides therapy for chlamydia, a fre-
quent coinfection. In much of the world, gonorrhoea management
involves a syndromic approach, using constellations of symptoms
toguideSTI treatmentwithoutdiagnostic tests. This approachworks
relatively well for men, who are more likely to have symptoms
indicative of gonococcal infection. In contrast, the vaginal discharge
syndrome is poorly predictive of N. gonorrhoeae cervical infection
[41,42]. Accurate N. gonorrhoeae nucleic acid amplification tests
(NAATs) exist but are expensive, can require laboratory infrastruc-
ture or equipment that is inaccessible in low-resource settings,
and do not yield rapid results. Use of Gram stain microscopy can
be a reliable, inexpensive diagnostic option for urethritis among
men, but is not reliable among women or for extragenital sites.
Many gonococcal infections are asymptomatic or unrecognised
but can still cause sequelae and be transmitted to sex partners and
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most settings, even those with access to NAATs, screening is only
recommended for groups at higher infection risk (e.g., MSM or
sex workers), primarily because of cost and feasibility concerns.
Several HICs with effective public health programmes that treated
symptomatic infection, screened key populations, treated patients’
sex partners, and promoted condom use experienced substantial
decreases in gonorrhoea incidence [43]. However, recent increases
in gonorrhoea, even in settings with full access to available inter-
ventions, and the added threat of gonococcal AMR, highlight the
fact that existing interventions are unlikely to be sufficient for con-
trolling gonorrhoea. Thus, gonococcal vaccines might be the best
hope for future sustainable control of N. gonorrhoeae infection.3. Strategic public health goals for gonococcal vaccines
Meeting participants discussed overarching public health goals
for gonococcal vaccines, considering the global epidemiologic con-
text and existing interventions. They highlighted the need for gono-
coccal vaccines with the ultimate goals of (1) preventing adverse
SRH outcomes and (2) reducing the impact of gonococcal AMR.
The experts noted the distinction between these goals and the
more immediate objective of preventing N. gonorrhoeae infections.
Prevention of infection is an outcome that can be easily measured
in trials and facilitates achieving the ultimate goals. Further discus-
sion will be needed for determining whether and how effects on
SRH outcomes and AMR can and should be measured more directly
in evaluating gonococcal vaccines, or whether measuring N. gonor-
rhoeae infection alone will be sufficient, along with bridging data to
other outcomes.
The long-term goal of preventing SRH-related disease can be
refined by specifying the highest priority N. gonorrhoeae-associated
outcomes, considering such consequences as upper-genital tract
morbidity among women (e.g., PID, infertility, ectopic pregnancy,
or chronic pelvic pain), adverse pregnancy outcomes, increased
HIV acquisition and transmission risk, ophthalmia neonatorum,
and other effects on SRH. However, to prioritize specific outcomes,
experts believe more data are needed regarding the precise global
burden of the outcomes and the potential impact of AMR. For
example, symptomatic urethritis among men might not be consid-
ered the most important health outcome from a relative morbidity
and mortality standpoint. However, if gonorrhoea became untreat-
able because of AMR, gonococcal urethritis would become much
more important.
Meeting participants emphasized the importance of including
AMR in the strategic public health goals. AMR has fuelled the
urgency for developing a vaccine and increased its value relative
to other approaches. However, addressing AMR alone is insuffi-
cient as the only goal, because the value of reducing the impact
of AMR stems from preventing the adverse SRH consequences of
gonorrhoea. Meeting participants were unclear regarding how
and when increasing AMR rates will translate into substantially
reduced, or absent, clinical therapeutic options, but all agreed that
gonococcal AMR represents a major global health threat. Given the
unmet need for gonococcal vaccines in all countries, the aim is
development of N. gonorrhoeae vaccines suitable for global use.4. Feasibility of developing gonococcal vaccines
4.1. Gonococcal bacteriology and immune response
N. gonorrhoeae are Gram-negative diplococci and obligate
human pathogens, which infect non-cornified epithelium in the
cervix, urethra, rectum, oropharynx, and conjunctivae. Symp-
tomatic infection is typically characterized by a neutrophilgranulocyte-rich purulent discharge. Gonococci have evolved com-
plex strategies for modulating and evading host innate and adap-
tive immune responses, including marked antigenic variability
[44,45]. Natural infection with N. gonorrhoeae does not appear to
provide protection against future infection, even with the same
strain, and repeated infections are common [45,46]. Clinical trials
with early gonococcal vaccines in the 1970s to early 1990s had dis-
appointing results [45], and no surrogates or correlates of protec-
tion are known for human infection. Given these challenges, the
feasibility of developing gonococcal vaccines had been in doubt
for decades. Progress has since been fuelled by advances in
whole-genome sequencing, proteomics, immunoproteomics, and
molecular pathogenesis research, through which several new, sta-
bly expressed candidate antigens have been identified [44,45].
New insights into the sophisticated mechanisms the gonococcus
uses to evade the human immune system have also been revealed
through studies with human immune cells and a mouse infection
model [47]. Lack of protective immunity after infection might be
related to induction of a Th17 response by N. gonorrhoeae that sub-
verts development of a protective Th1 response [48]. Protection
might also be impeded by antibodies against the surface protein
Rmp that block the activity of antibodies against other surface
molecules [49]. Gonococcal vaccines will need to induce a protec-
tive immune response that is superior to that generated during
natural infection.4.2. Serogroup B meningococcal vaccines and gonorrhoea
Optimism about the biologic feasibility of gonococcal vaccine
development has been reenergized because of accumulating obser-
vational data related to vaccines developed for preventing disease
from serogroup B N. meningitidis, a pathogen closely related to N.
gonorrhoeae. After a mass vaccination campaign with a meningo-
coccal group B outer membrane vesicle (OMV) vaccine in New
Zealand (MeNZB), a large case-control study demonstrated that
gonorrhoea case-patients were significantly less likely than
control-patients to have been vaccinated [5]. The estimated vac-
cine effectiveness, after controlling for potential confounders,
was 31% (95% confidence interval [CI]: 21%–39%). This effect
appeared to be short-lived, and less reduction was observed for
coinfections of N. gonorrhoeae and C. trachomatis. However, the
findings were intriguing. A subsequent retrospective cohort study
in New Zealand revealed that MeNZB vaccination was associated
with a reduced rate of gonorrhoea-associated hospitalizations
[50]. Although limited by small numbers, among those people vac-
cinated during adolescence, the hospitalization study estimated an
adjusted vaccine effectiveness of 47% (95% CI: 18%–66%). Ecologic
data from Cuba and a small observational study from Quebec also
support apparent decreases in gonorrhoea incidence after use of
OMV-based meningococcal vaccines [51,52].
Several basic science studies have followed up on the observa-
tional data. OMVs are produced by Neisseria species during natural
infection and in vitro culture and can be purified [53]. An 80%–90%
nucleotide identity exists between N. meningitidis and N. gonor-
rhoeae, and several antigens present in meningococcal B OMVs
are conserved in N. gonorrhoeae [54]. The New Zealand vaccine
MeNZB is no longer available, but the MeNZB OMV antigen is a
component of the licensed 4-component meningococcal serogroup
B vaccine 4CMenB (Bexsero, GSK). In one study, antibodies from
people vaccinated with 4CMenB recognized gonococcal antigens,
which might contribute to the predicted cross-protection of these
vaccines [54]. In a recent study, 4CMenB accelerated clearance of
N. gonorrhoeae in a mouse genital tract infection model [55]. With
the observational data, these studies provide encouragement that
gonococcal vaccines are biologically feasible.
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Recent reviews have summarized the most promising antigenic
targets, immunologic approaches, and current research and devel-
opment efforts for vaccines against N. gonorrhoeae [7,44,45,56]. A
number of stably expressed conserved antigens might be promis-
ing gonococcal vaccine targets. The main vaccine approaches
include meningococcal OMV vaccines, gonococcal OMV vaccines,
a lipooligosaccharide epitope vaccine, and purified protein subunit
vaccines [7]. Additional strategies involve formalin-inactivated
whole-cell N. gonorrhoeae, virus-like particles, DNA or mRNAs
[57]. Promising gonococcal vaccine candidates using these
approaches are undergoing evaluation in animal models, with a
variety of different antigen-delivery systems and adjuvants. Novel
vaccine delivery systems include viral vectors, protein scaffolds,
liposome preparations, nanoparticles or nanodiscs, and microarray
patches [7,45,57].
Preclinical evaluation of gonococcal vaccine candidates is pri-
marily conducted in mouse models with well-characterized fea-
tures of female N. gonorrhoeae infection [44,45]. Transgenic
mice have been developed to alleviate some host restrictions,
although mice cannot fully mimic human infection or disease
[45]. A controlled human infection model with N. gonorrhoeae
exists, but for safety reasons is limited to experimental urethral
infection among male volunteers. The model is not widely avail-
able, and the window of study is 1–6 days before infection is
treated [58]. Nonetheless, it can be used to measure antibodies,
cytokines, and cell subsets upon infection and can provide a rel-
atively rapid and less expensive way to conduct preliminary
evaluations of vaccine candidates among humans. As of Novem-
ber 2019, no new gonococcal vaccine candidates were being
evaluated in human clinical trials; however, clinical trials of
licensed meningococcal group B vaccines for preventing gonococ-
cal infections are planned for 2020.5. Understanding the potential value of gonococcal vaccines
WHO assessments of the global value of vaccines aim to identify
and articulate the potential value of a vaccine from the perspective
of stakeholders in both LMICs and HICs, and for individual- and
population-based health, economic, and societal benefits. Vaccines
often take 12–15 years to develop at costs of US$1 billion, and
vaccine development programmes often fail [59]. To attract suffi-
cient investment in gonococcal vaccine development, investors
and vaccine developers will need to be convinced that gonococcal
vaccines are technically feasible and commercially viable. How-
ever, beyond the economic investment case, WHO vaccine value
assessments convey the range of effects a vaccine can have in
meeting global public health and societal needs, which can guide
policy and programme decision-makers in addition to vaccine
developers and funders. Along with traditional economic assess-
ments (e.g., cost-effectiveness analyses), such assessments con-
sider overall reductions in disease incidence, impact on
programmatic or health systems, and other social and economic
benefits. Vaccine efficacy and disease burden need to be consid-
ered in the context of vaccine acceptability, affordability, and pro-
grammatic feasibility, and this can vary by setting. Thus, public
health value of vaccines assessments also include country-level
input and perspectives.
After reviewing the need and strategic public health goals of
gonococcal vaccines and their technical feasibility, meeting partic-
ipants reviewed models of potential vaccine impact, perspectives
on gonococcal vaccines from different countries and regions, and
other considerations for developing a global public health value
assessment.5.1. Modelling of predicted gonococcal vaccine impact
Mathematical modelling studies can contribute to multiple
aspects of the value assessment and PPC process [60]. Modelling
can be used to predict current and future trends in N. gonorrhoeae
infection, disease, and AMR, and the potential impact of gonococcal
vaccines [61–63]. The basic reproduction number (R0) for gonor-
rhoea, or maximum potential for a single infection to spread within
a population, is believed to be low [64], indicating that a vaccine
might not require high efficacy to have substantive population
effects [65]. Two modelling studies predicted that, even with gono-
coccal vaccine efficacy of only 20%, lower than that observed in the
New Zealand case-control study of serogroup B meningococcal
vaccine [5], vaccination could result in a substantial decrease in
N. gonorrhoeae infections [61,63]. One model also predicted that
vaccination can reduce the spread of gonococcal AMR [62]. Assum-
ing all adolescents aged 13 years in a population received a non-
waning gonococcal vaccine with 50% efficacy, or a 100%
efficacious vaccine waning after 7.5 years, modellers predicted that
gonococcal infection prevalence might be reduced by 90% after
20 years [61]. Similar results were generated assuming only key
population members were vaccinated, with 75% coverage [61].
Modelling has also been used to estimate gonorrhoea-
associated costs. Direct medical costs of gonorrhoea cases in the
United States were estimated at $162 million during 2008 [66].
Another model estimated that emerging ceftriaxone resistance
might lead to 1.2 million more gonococcal infections over 10 years,
costing $378.2 million [67]. Cost models from LMICs are limited,
although estimates of implementation costs for the WHO Global
Health Sector Strategy on STIs [3] includes costs of syndromic
management of gonorrhoea for general populations and screening
and treatment for key populations [68]. Intervention cost-
effectiveness modelling is limited for all settings, particularly tak-
ing into account increasing AMR [63]. For the best predictive value,
models require high-quality data inputs (see Section 7 for data
needs).
5.2. Country and regional perspectives
Two panels of representatives from countries and regions pro-
vided perspectives about the need and potential public health
value of gonorrhoea vaccines in the context of country- and
regional-level epidemiology, AMR, and health care delivery, as well
as local awareness, policy, and likely vaccine acceptability. The
countries represented included Brazil, China, Kenya, South Africa,
Thailand, the United States, and Zimbabwe. WHO Regional Advi-
sors from the Americas and the Western Pacific Region and the
European Centre for Disease Prevention and Control also provided
input. Participants highlighted the widely varying prevalence of
gonorrhoea between and within countries, which might affect
the perceived value of vaccines in different settings. In the majority
of countries, gonorrhoea prevalence is lower than that of the other
common bacterial STI — chlamydia — but prevalence of both STIs
can be high among certain populations (e.g., young women at high
risk for HIV acquisition in sub-Saharan Africa) [11]. The increasing
threat from gonococcal AMR is a concern across countries, given
global transmission of AMR N. gonorrhoeae strains. Certain country
representatives (e.g., Thailand’s) mentioned special considerations,
including sex tourism, which can foster the global transmission of
gonococcal AMR.
Lack of valid in-country prevalence and incidence data regard-
ing gonococcal infection and AMR has hampered awareness and
policy attention in many settings. STI care in the private sector
and use of syndromic management can make data collection more
difficult. Additionally, in some countries, a focus on HIV has dis-
tracted policymakers from investment in other STIs. However,
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rhoea and syphilis in HICs, and reports of treatment failures caused
by gonococcal AMR have provided new opportunities for increased
policy interest in gonococcal vaccines. In the United States, where
infection and AMR surveillance data have been collected for years,
drug-resistant N. gonorrhoeae is 1 of 3 pathogens considered to be a
top-level urgent threat to be addressed by the government [69].
Some meeting participants questioned whether ministries of
health might need to see clear trends of increasing morbidity from
gonococcal AMR before allocating resources for gonococcal vac-
cines. Because gonorrhoea causes multiple types of morbidity but
is typically not life-threatening, making the case for gonococcal
vaccines to national policymakers can be more challenging. Cost-
effectiveness data and a clear understanding of the adverse out-
comes caused by gonorrhoea in local settings will be crucial for
policy decision-making.
Although STI experts recognize the importance of controlling
gonorrhoea given increasing AMR globally, awareness and knowl-
edge of gonorrhoea and its potential disease outcomes among the
public is relatively low in many countries [59]. For example, fertil-
ity is typically of substantial concern; however, the link to gonor-
rhoea and other STIs is not always recognized, and infertility
prevention is not always prioritized by those allocating resources.
Moreover, stigma regarding STIs, including gonorrhoea, is high and
might be compounded in settings where a large burden of infection
is among marginalized populations. That stigma can be a factor in
acceptability of gonococcal vaccines. Human papillomavirus (HPV)
vaccines are often promoted as anticancer vaccines rather than STI
vaccines because of concerns regarding lower acceptability.
Although populations are becoming aware of AMR, they might
know less about gonococcal AMR specifically or believe they are
not at risk. Some countries are focusing on youth health, which
participants posited as an opportunity for positioning gonococcal
vaccines because adolescents and young adults are particularly
vulnerable to STIs.
5.3. Gonococcal AMR and other considerations regarding public health
value
Meeting participants agreed that gonococcal vaccines are
needed and would have value, but believed that available informa-
tion is insufficient for fully quantifying the value and determining
whether vaccine introduction is justified in all settings. A recent
global report on AMR and vaccine development highlighted the
strong case for advancing research and development for gonococ-
cal vaccines because of high N. gonorrhoeae incidence, high mor-
bidity, and circulation of AMR strains [4]. In addition to needing
better, updated information about global gonococcal-related dis-
ease burden, a key consideration is how much gonococcal AMR is
likely to increase, over what period, and how that might translate
into treatment failures, lengthier and more costly treatment regi-
mens, and increases in infection and disease outcomes. Another
uncertainty is how best to measure and ascribe a value to the
AMR threat and the potential role of vaccines in addressing it.
Gonococcal AMR is only one part of a global problem. Antibiotic
use or misuse for one infection can select for AMR in other patho-
gens, and reducing antibiotic use through a vaccine could reduce
AMR for multiple pathogens [70]. WHO and other partners are
developing a value attribution framework for vaccines against
antimicrobial resistance for modelling these complex interactions
[71].
The value of gonococcal vaccines will also need to be considered
in the context of other available interventions, which might vary
according to the status of AMR. At least 2 new antibiotics for gon-
orrhoea are in clinical trials, but this therapeutic area lacks strong
commercial interest, and when a candidate will become availablefor clinical use remains unclear [72]. Additionally, N. gonorrhoeae
has developed or acquired resistance to multiple classes of antibi-
otics over time. Additional interventions are also being studied
(e.g., microbicides, oropharyngeal mouthwashes [73], and different
packages of care) as are a range of novel AMR strategies, including
antibodies, immune stimulants, and bacteriophages, which could
all be reviewed within a value assessment [4].6. Key considerations for gonococcal vaccine PPCs
Meeting participants discussed key considerations for gonococ-
cal vaccine PPCs as a starting point for developing a formal WHO
PPC document through a multistep consultative process [8]. The
discussions focused on preferences for LMICs in addition to HICs
to encourage development of gonococcal vaccines for global use.
6.1. Vaccine indications
Vaccine indications reflect the main prevention outcomes to be
evaluated in vaccine clinical trials and provide the basis for licen-
sure application. The choice of indication has implications for the
feasibility of measuring outcomes and demonstrating efficacy
and for eventual vaccine licensure and marketing. Prevention of
N. gonorrhoeae infection is the vaccine indication that most easily
addresses both overarching public health goals expressed by meet-
ing participants: preventing N. gonorrhoeae-associated SRH mor-
bidity and combating gonococcal AMR. Testing for infection can
be performed easily and accurately in clinical trials, and reductions
should translate into reductions in broader disease outcomes.
However, demonstrating efficacy with a disease indication might
be easier, because a vaccine might prevent disease to a greater
extent than infection (e.g., by preventing N. gonorrhoeae ascension
to the upper-genital tract rather than completely preventing infec-
tion). Conversely, a vaccine might disproportionately prevent
infections that are less likely to cause sequelae. Disease endpoints
and indications are often preferred by regulators (although not
exclusively so) and might be easier to market. However, the choice
of disease-related primary indications for gonococcal vaccines can
be challenging. Among women, both symptomatic cervical infec-
tions and upper-genital tract infections (e.g., PID) are difficult to
measure and confidently ascribe an aetiology. Further, even with
prevention of disease, remaining asymptomatic infections could
still propagate AMR. Although acquisition of AMR N. gonorrhoeae
strains by individuals could be measured in vaccine trials, the
likely benefit of vaccines in reducing the impact of AMR would
be at a population level, because of reduced infections more
broadly. Further review and discussion is needed for gaining final
consensus regarding gonococcal vaccine indications, and new data
(e.g., about correlates of protection or biomarkers of disease) might
change the discourse.
6.2. Target populations
Wide variability in gonorrhoea epidemiology between and
within countries guided discussion of preferred target populations
for gonococcal vaccines. Meeting participants agreed that, in coun-
tries with relatively high prevalence of gonorrhoea among young
sexually active populations, broad-based vaccination during early
adolescence, aiming for presexual debut (e.g., the primary target
age for HPV vaccination, ages 9–14 years) would be preferred
[74]. More information might be needed, particularly cost-
effectiveness modelling, to determine for how many countries or
settings this target population for vaccination would be most
appropriate, and according to which levels of prevalence, vaccine
efficacy, and duration of protection. In areas where gonorrhoea
Table 1
Gaps in knowledge and data and research needs for gonococcal vaccine development.
Area Data gap or research need Notes and additional considerations
Obtaining better epidemiologic data regarding Neisseria gonorrhoeae (Ng) infection, disease, antimicrobial resistance (AMR), and natural history
Infection  Improve global and regional estimates of Ng infection
 Obtain prevalence and incidence data regarding Ng infection
from more settings and populations
 Evaluate overlap of Ng infection epidemiology with that of
meningococcal serogroup B infection and introduction of
meningococcal B vaccines across countries
 Development and validation of cheap, feasible Ng diagnostic tests
is crucial for obtaining better data, especially for low- and middle-
income countries (LMICs) [84]
 Conduct strategically determined, additional prevalence studies
in selected LMIC areas where most data are being imputed
 The World Health Organization (WHO) has published a standard
protocol for conducting gonorrhoea prevalence surveys in antena-
tal settings [85]
 Use of existing Ng infection data from clinical trials (e.g., HIV pre-
vention, human papillomavirus (HPV) vaccine, maternal studies)
should be explored
Disease  Improve global and regional estimates of Ng-associated clinical
and disease outcomes
 Obtain prevalence and incidence data regarding Ng-associated
disease from more settings and populations, particularly in
LMICs
 Determine attributable fractions of such outcomes as PID and
tubal factor infertility (TFI) caused by gonorrhoea
 Outcomes can include urethral discharge, pelvic inflammatory
disease (PID), infertility, ectopic pregnancy, chronic pelvic pain,
adverse birth outcomes, ophthalmia neonatorum and other eye
disease, Ng-associated HIV infection, and other outcomes (e.g.,
epididymitis, proctitis, disseminated gonococcal infection, or
male infertility)
 Systematic reviews can be conducted first to summarize what is
currently known about overall disease burden (e.g., all infertility
or all TFI), about Ng-associated disease burden (e.g., Ng-associ-
ated PID and infertility), and about the methods used for attribut-
ing etiology to Ng (e.g., Ng serologic tests)
 Updated etiologic studies of PID using cervical testing and of the
proportion of infertility that is tubal factor [34], are needed in
diverse settings
 Improved methods for measuring upper-genital tract disease (e.g.,
biomarkers, radiology, or case definitions) and for measuring past
Ng infection (e.g., improved serologic tests) would be valuable
 Explore potential data sources regarding gonorrhoea-associated
adverse pregnancy outcomes
AMR  Obtain more globally representative assessments of Ng AMR,
transmission, and clinical treatment failures
 Determine trends in Ng AMR in more settings and among more
populations
 Increase number of countries testing gonococcal isolates for AMR
and reporting through WHO’s Gonococcal Antimicrobial Surveil-
lance Programme (GASP) [2]
 Improved diagnostic tests, including rapid tests for Ng AMR
would aid evaluation
 Systems are needed for identifying and reporting clinical treat-
ment failures for gonorrhoea and other key AMR metrics (e.g.,
sentinel surveillance sites in LMIC settings)
Natural history and
transmission
 Improve understanding of the proportion, predictors, and timing
of Ng cervical infections ascending to the upper-genital tract,
causing PID and resulting in long-term sequelae
 Gain insight into the factors associated with acquisition, trans-
mission, and duration of infection, including at multiple
anatomical sites
 Innovative, ethical study designs are needed for assessing the nat-
ural history of Ng infection
 Explore study designs used for understanding chlamydia natural
history and their role in evaluating gonorrhoea (e.g., evaluating
rates of PID in the interval between testing and treatment [86]
or using serial specimens from existing prospective studies)
 Couples studies might help researchers understand transmission
from different anatomical sites and other factors like bacterial
load
Modelling gonococcal infection, disease, AMR, economic burden, and theoretical vaccine impact and cost-effectiveness
Overall  Review and summarize the models that have been published,
are ongoing, or are planned
 Determine priority data needs for robust modelling
 Prioritize and coordinate modelling efforts across groups, initia-
tives, and interventions
 Modelling efforts related to gonorrhoea across different initiatives
(e.g., AMR) and interventions (e.g., new antibiotic development)
will need to be coordinated to increase model efficiency and
utility
 Strengthened data on burden of infection, disease, AMR, transmis-
sion, and natural history is important for all models
 Consensus regarding a plausible range of important model
assumptions will be valuable
 Model comparisons can strengthen robustness of conclusions
from modelling studies
Models of Ng infection,
disease, AMR, and
economic burden
 Develop dynamic models of Ng infection, disease, and AMR in
varied settings
 Estimate global and regional economic burden of Ng infection
and disease
 Predict future trends in Ng infection, disease, AMR, and costs
 Improve data for modelling inputs and assumptions, including
information about key populations and sexual networks
 Modelling can be difficult for low prevalence infections with
heterogenous distribution within the population
 Predictions of the effect of increasing AMR on infection and dis-
ease incidence and on costs can help refine the value of a vaccine
Vaccine impact models  Model the potential effectiveness of a future Ng vaccine in the
context of the observed epidemiology and disease burden in dif-
ferent settings
 Model potential vaccine impact against different assumptions
and scenarios
 How to value AMR, a vaccine’s potential effect on AMR, and a vac-
cine’s impact in the context of AMR will be key to understanding
overall vaccine impact and value
 Understanding vaccine impact considering different target popu-
lations, immunization strategies, and efficacies can guide PPCs in
addition to value propositions
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Table 1 (continued)
Area Data gap or research need Notes and additional considerations
 Models should consider both high-income countries (HICs) and
LMIC settings




 Model the potential cost-effectiveness of a future Ng vaccine
given the observed and predicted health and economic burden
in different settings
 Model potential cost-effectiveness against different assumptions
and scenarios
 Systematic reviews can assess what is known about gonorrhoea
health care–seeking and –usage, and costs of care and treatment,
for both infection and disease
 Work will be needed to refine estimates of disability adjusted life-
years and quality adjusted life-years considering all Ng outcomes
 Cost-effectiveness analyses can guide preferred product charac-
teristics (PPCs) in addition to value assessments
Advancing basic science, translational, immunobiologic, and clinical research
Experimental systems  Refine animal models and in vitro systems to expand the range
of features of human infections that can be studied and to enable
vaccine candidate assessment
 Explore and optimize use of controlled human infection models
(CHIMs) to study Ng immune responses and vaccine efficacy
 Continued understanding of complex Ng immunobiology can lead
to new target antigens, novel adjuvant, or delivery systems
 Improved preclinical systems for evaluating vaccine candidates
can facilitate entry into clinical evaluation
 Better data about pathogenesis and immunity in human infec-
tions can be compared with animal models to refine them
 Current CHIMs exist only for male urethral infection, but could be
developed for others (e.g., postmenopausal women)
Antigen discovery and
vaccinology
 Continue to take advantage of new technologies to screen for
new antigenic targets and define the most promising list of can-
didates [7,44,45,56]
 Further define mechanisms of immunity and immune evasion,
which could help in developing adjuvants and delivery plat-
forms for Ng vaccines
 Evaluate vaccine candidates in preclinical models or CHIMs
 Evaluation of vaccine candidates is challenging, given that no
established surrogate markers or correlates of protection against
Ng exist
 Given antigenic variability of Ng, a combination of antigens might
be needed to provide broad protection against different Ng strains
 Findings related to meningococcal outer membrane vesicle (OMV)
vaccines and possible cross-protection for Ng can provide direc-




 Conduct studies to obtain better data on human immune
responses to Ng infection, including prospective evaluations of
responses associated with reinfection
 Evaluate the effect of licensed meningococcal serogroup B OMV
vaccines on Ng acquisition
 Evaluate the effect of coinfections, the microbiome, and hor-
monal status on Ng infection, disease, and immune response
 Better understand the role of oropharyngeal and rectal infection
in Ng transmission and promotion of AMR
 Facilitate progression of promising preclinical candidates into
clinical evaluation as soon as possible
 Clinical studies are needed to examine host factors and immune
responses during Ng infection, and those predicting the likelihood
of infection, reinfection, or ascension to the upper-genital tract
 Innovative studies can be modelled on those conducted for
chlamydia (e.g., studies reporting that clearance of infection
between testing and treatment is linked with reduced risk for
repeat infection) [87]
 People with an increased risk for complicated Ng disease from
complement disorders can provide clues to correlates of risk
and protection [88]
 Efficacy of meningococcal serogroup B vaccines ideally will be
evaluated through clinical trials specifically designed for examin-
ing efficacy against Ng infection or disease acquisition; prospec-
tive observational studies as the vaccines are rolled out in new
areas can also add insight
 Couples studies might be useful for evaluating transmission and
factors associated with transmission
 Correlates of protection might be difficult to identify but would be
highly useful; although not essential for vaccine development and
licensing, they can make bridging studies easier
Encouraging investment and planning for policy and implementation decisions in advance
Value assessment and
PPCs
 Consolidate data on burden of disease, economic burden, and
vaccine impact and cost-effectiveness
 Understand drivers of gonococcal vaccine development and who
the main stakeholders are
 Obtain country-level input regarding the potential value of Ng
vaccines and features of a vaccine that would be essential and
those that would be desirable in different settings
 Improving the quantity and quality of underlying disease data is
crucial for developing the vaccine value assessment and PPCs
 Considering the interests and needs of different stakeholders is
vital (e.g., WHO’s Strategic Advisory Group of Experts, Gavi, the
Vaccine Alliance, funders, vaccine developers, national policy-
makers, health care providers, individuals at risk, parents, and
civil society)
 Value-of-vaccines assessments consider more than just health
benefits and can also include broader societal and public value
Acceptability and
implementation
 Evaluate the level of awareness and knowledge about gonor-
rhoea and Ng AMR and risk perception among young people
and their parents, health care providers, and policymakers
 Obtain country-level information regarding the likely accept-
ability of and demand for Ng vaccines from a broad range of
countries
 Evaluate the potential acceptability of Ng vaccines and potential
barriers to acceptance or uptake by individuals and communi-
ties for different populations and settings
 Assess the potential delivery systems for gonococcal vaccines for
different target populations in varied health care systems
 Increasing awareness of Ng AMR and treatment failures can affect
both awareness and demand for Ng vaccines
 Understanding potential acceptability of Ng vaccines and how
they would be used, including country-level input, early in vac-
cine development can help guide development of vaccines that
are suited for global use and able to be implemented more quickly
upon licensure and pre-qualification
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among specific population groups, an alternative strategy would
be targeting key populations. Certain groups (e.g., adolescent girls
and young women in southern Africa and MSM) not only have
higher gonococcal infection rates but are also at higher risk for
HIV infection, which can be increased further during gonococcal
infection. The global market for such population groups as MSM
is likely to be relatively small, which will be a consideration for
vaccine developers.
A focus on the period just before sexual debut is based on the
need for peak protection during the time of highest incidence,
which among general populations is typically during late adoles-
cence and young adulthood. However, unlike HPV, whether people
with prior exposure to N. gonorrhoeae might be more difficult to
immunize than someone who is naïve to infection is unclear.
Although induction of blocking antibodies to Rmp during natural
infection might be a concern for OMV vaccines that contain this
protein [49], this would not be a consideration for protein subunit
vaccines or OMV vaccines in which the rmp gene is deleted. It is
also possible that prior gonococcal infection might prime the
immune system, resulting in a booster effect with vaccination.
Duration of vaccine protection is a key consideration for determin-
ing the appropriate age at vaccination. Evidence regarding
meningococcal serogroup B vaccines suggests possible cross-
protection might be short-lived [5].
Meeting participants discussed whether the preferred target
population should include both females and males. Because infec-
tion among both sexes can contribute to and be affected by AMR,
both have disease consequences, and for general equity reasons,
meeting participants favoured vaccination of both sexes. The most
direct serious disease outcomes of gonococcal infection (e.g., infer-
tility or adverse pregnancy outcomes) are among women, and
single-sex vaccination can provide benefits for both sexes through
herd immunity. WHO recommends HPV vaccination of adolescent
girls only, on the basis of direct benefits for cervical cancer preven-
tion and cost-effectiveness evaluations indicating limited incre-
mental benefit of vaccinating adolescent boys among general
populations if high coverage (>80%) is reached among girls [74].
Nonetheless, a number of countries (e.g., Australia, Brazil, the Uni-
ted States) have implemented HPV vaccination for boys as well.
Further, MSM are often key populations for maintaining gonor-
rhoea transmission within HICs. Modelling and cost analyses con-
sidering differing scenarios for target populations and further
information about the attributes of candidate gonococcal vaccines
can help refine the discussion.
6.3. Programmatic delivery considerations
Programmatic delivery considerations are inextricably linked to
intended vaccine target populations. Expanding global experience
with HPV vaccination programmes makes reaching adolescent
populations increasingly feasible, and new vaccines can be added
to this platform, with shared delivery costs. Countries delivering
HPV vaccine only to adolescent girls might need to adjust their
programmes if gonococcal vaccines are recommended for both
sexes. Vaccination programmes targeted to key populations have
been difficult to implement in the past [75]. However, expansion
of PrEP and other HIV prevention programmes to key populations
might provide more efficient platforms for targeted vaccination.
Further, if gonococcal vaccines have adequate efficacy among those
with prior infection, or even a booster effect, administering the
vaccine to people with diagnosed gonorrhoea, or their partners,
would be a tailored way of finding those at highest risk.
Vaccine acceptability and coverage rates vary by country and
vaccine. Many countries achieve excellent coverage rates for most
vaccines and vaccines are highly acceptable. Other countries are,however, increasingly affected by vaccine hesitancy. Demonstra-
tion of safety and efficacy is always essential, but other factors
can contribute to vaccine hesitancy, particularly for STI vaccines.
Hepatitis B virus and HPV are STIs, but these vaccines are not pro-
moted as STI vaccines but rather as hepatitis/hepatic cancer– and
cervical cancer–prevention vaccines, respectively. Promoting
gonococcal vaccines as anything other than STI vaccines might be
difficult. Although a vaccine that helped preserve fertility or
healthy pregnancies might be acceptable, these gonococcal disease
outcomes have many possible causes, and the contribution of N.
gonorrhoeaewill be harder to evaluate in trials and thus to promote
directly.
Combination vaccines are another consideration. Many practi-
tioners believe that to target PID and other infectious
reproductive-tract conditions, a dual gonococcal-chlamydial vac-
cine is desirable [59]. Both infections are STIs with similar sites
of infection and disease outcomes, although their immunobiology
and epidemiology have key differences. Development pathways
are typically more straightforward and less resource-intensive for
stand-alone vaccines than for combination vaccines. These prod-
ucts are often developed and evaluated separately, then combined.
However, licensed serogroup B meningococcal vaccines might
demonstrate some cross-protection against gonorrhoea, which
could provide a short-cut to a combined meningococcal-
gonococcal vaccine. Incidence of the different serogroups of
meningococcal infection, and thus recommendations for
serogroup-specific meningococcal vaccines, vary widely across
countries and populations [76]. Meningococcal serogroup B vacci-
nes are recommended in a relatively limited number of countries,
primarily HICs. A meningococcal-gonococcal vaccine might be
used more broadly. Trials directly evaluating the efficacy of
licensed meningococcal serogroup B vaccines against gonorrhoea
will provide information for determining the potential for com-
bined versus stand-alone gonococcal vaccines.7. Research and data needs
Meeting participants identified research and data needs that are
crucial for assessing the public health value and for defining PPCs
for gonococcal vaccines. Table 1 displays these research and data
needs according to the key activities outlined in the Global STI Vac-
cine Roadmap, as follows: (1) obtaining better epidemiologic data
regarding infection, disease, AMR, and natural history; (2) mod-
elling predicted infection, disease, and AMR trends, economic bur-
den, and theoretical vaccine impact and cost-effectiveness; (3)
advancing basic science, translational, immunobiologic, and clini-
cal research; and (4) encouraging investment and planning for pol-
icy and implementation decisions in advance [6–7,77].8. Conclusion
Public health interest in developing vaccines for gonorrhoea has
grown dramatically in recent years, given increasing gonococcal
AMR and promising evidence that gonococcal vaccines might be
biologically feasible [2,5]. The 2019 WHO global stakeholder con-
sultation on gonococcal vaccines focussed on the potential value
of gonococcal vaccines, the characteristics they should have to
optimize their global public health value, and how such vaccines
might be used, if available. Meeting participants emphasized that,
with respect to broad public health goals, gonococcal vaccines
should address both the disease outcomes of gonorrhoea and the
increasing threat of gonococcal AMR. To better understand the full
potential benefit that gonococcal vaccines can have in reaching
these goals, the experts stressed the need to fill several data gaps.
These gaps include more precisely quantifying the magnitude of N.
S.L. Gottlieb et al. / Vaccine 38 (2020) 4362–4373 4371gonorrhoeae-associated disease burden for such outcomes as infer-
tility and modelling the predicted role of gonococcal vaccines in
controlling gonococcal infections in the context of AMR or in
reducing the impact of gonococcal AMR more directly. These data
will be crucial for assessing the global health, economic, and soci-
etal value of gonococcal vaccines, which can justify investment and
aid decision-making about future vaccine policy and programmes.
Meeting discussions concerning gonococcal vaccine indications,
target populations, infection and disease endpoints, and relevant
vaccination strategies provide the basis for comprehensive PPCs
for gonococcal vaccines to encourage development of vaccines
suitable for both LMIC and HIC contexts. These epidemiologic, pro-
grammatic, and policy considerations should be addressed in par-
allel with advancing preclinical and clinical research and
development, including direct assessment of the ability of
meningococcal serogroup B OMV vaccines to prevent gonorrhoea.
These activities, together, can help catalyse development of viable
gonococcal vaccines and realize a long-awaited innovation in the
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